EUVIMEDEUVIMED entdecken
EditorialOpen Access

Pitfalls and perils from FDA-approved germ-line cancer predisposition tests

Wafik S El-Deiry, Eli Y Adashi

Oncotarget · 2024

DOI: 10.18632/oncotarget.28677 ↗

Kurz gefasst

Editorial in der Zeitschrift Oncotarget, 2024. Verfasst von Wafik S El-Deiry und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Genetic Predisposition to Disease, Genetic Testing. Die Arbeit nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

United States Food and Drug AdministrationGenetic Predisposition to DiseaseGenetic TestingHumansUnited StatesNeoplasmsGerm-Line MutationGenetic CounselingDirect-To-Consumer Screening and Testing

Stichwörter der Autor:innen

cancer predispositiondirect to consumergermlinehereditary cancermarketing authorization

Zitieren

APA

El-Deiry, W. S., & Adashi, E. Y. (2024). Pitfalls and perils from FDA-approved germ-line cancer predisposition tests. Oncotarget. https://doi.org/10.18632/oncotarget.28677

Vancouver

El-Deiry WS, Adashi EY. Pitfalls and perils from FDA-approved germ-line cancer predisposition tests. Oncotarget. 2024. doi:10.18632/oncotarget.28677

BibTeX
@article{ElDeiry2024,
  author = {El-Deiry, Wafik S and Adashi, Eli Y},
  title = {Pitfalls and perils from FDA-approved germ-line cancer predisposition tests},
  journal = {Oncotarget},
  year = {2024},
  doi = {10.18632/oncotarget.28677}
}
Kostenlos starten →